Skip to content

Sofie L. Valk

Max Planck Institute for Human Cognitive and Brain Sciences

2 papers in the library · 2 citations · publishing 2024-2026

Papers

ENIGMA-Meditation: Worldwide consortium for neuroscientific investigations of meditation practices

April 8, 2024 Saampras Ganesan, Aki Tsuchiyagaito, Greg J. Siegle et al. 2 citations preprint

Meditation practices, which have been adapted into manualized interventions for conditions like depression, pain, addiction, and anxiety, show therapeutic promise, but their neuroscientific basis remains unclear. Current neuroimaging studies rely on small, heterogeneous datasets that vary in practice types, participant experience, clinical targets, and imaging methods, limiting generalizability and replicability. To address this, the ENIGMA-Meditation consortium was formed as a global collaboration to conduct systematic meta- and mega-analyses of distributed neuroimaging data using standardized methods. This framework aims to improve statistical power and rigorously characterize the neural mechanisms underlying meditation's effects on psychological and cognitive attributes, advancing the field of contemplative neuroscience.

Whole-brain drug distribution profiles of psychedelic drugs provide insights into rapid antidepressant action

bioRxiv (Cold Spring Harbor Laboratory) April 7, 2026 Benjamin Hänisch, Tobias Kaufmann, Sofie L. Valk

Combining pharmacodynamic profiles of four classic hallucinogens and ketamine with receptor density distributions from PET and autoradiography studies produces anatomical distribution profiles of drug action strength. Classic hallucinogens show high action strengths in association cortices and, based on autoradiography, in supragranular layers and multimodal temporal areas. Ketamine's affinity for high-affinity subtypes of 5-HT2a and D2 receptors generates classic hallucinogen-like neuroanatomical trends. High rapid-acting antidepressant action strengths in emotion-processing regions contribute to understanding the mechanism of rapid antidepressant action.